Once daily formulations of tetracyclines
DC CAFCFirst Claim
Patent Images
1. An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μ
- g/ml and a maximum of 1.0 μ
g/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline;
(ii) a delayed release (DR) portion comprising 10 mg doxycycline; and
optionally, (iii) one or more pharmaceutically acceptable excipients.
3 Assignments
Litigations
1 Petition
Accused Products
Abstract
Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
91 Citations
29 Claims
-
1. An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μ
- g/ml and a maximum of 1.0 μ
g/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline;
(ii) a delayed release (DR) portion comprising 10 mg doxycycline; and
optionally, (iii) one or more pharmaceutically acceptable excipients. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 22)
- g/ml and a maximum of 1.0 μ
-
19. A method for treating rosacea in a mammal in need thereof, comprising administering an oral pharmaceutical composition of doxycycline comprising, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μ
- g/ml and a maximum of 1.0 μ
g/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline;
(ii) a delayed release (DR) portion comprising 10 mg doxycycline; and
optionally, (iii) one or more pharmaceutically acceptable excipients. - View Dependent Claims (20, 21)
- g/ml and a maximum of 1.0 μ
-
23. A delayed-release tablet of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μ
- g/ml and a maximum of 1.0 μ
g/ml, the tablet consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline in the form of tablet;
(ii) a delayed release (DR) portion comprising 10 mg doxycycline; and
, optionally, (iii) one or more pharmaceutically acceptable excipients. - View Dependent Claims (24, 25, 26, 27)
- g/ml and a maximum of 1.0 μ
-
28. A method for treating rosacea in a mammal in need thereof, comprising administering to the mammal a delayed-release tablet of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μ
- g/ml and a maximum of 1.0 μ
g/ml, wherein the tablet consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline in the form of tablet;
(ii) a delayed release (DR) portion comprising 10 mg doxycycline; and
optionally, (iii) one or more pharmaceutically acceptable excipients. - View Dependent Claims (29)
- g/ml and a maximum of 1.0 μ
Specification